{"id":389928,"date":"2021-12-24T00:00:00","date_gmt":"2021-12-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0009-2021-biopharma-renal-cell-carcinoma-disease-landscape-forecast-g7-2021\/"},"modified":"2026-04-25T11:31:30","modified_gmt":"2026-04-25T11:31:30","slug":"dlsfon0009-2021-biopharma-renal-cell-carcinoma-disease-landscape-forecast-g7-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0009-2021-biopharma-renal-cell-carcinoma-disease-landscape-forecast-g7-2021\/","title":{"rendered":"Renal Cell Carcinoma | Disease Landscape &#038; Forecast | G7 | 2021"},"content":{"rendered":"<p>The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb \/ Ono Pharmaceutical), Keytruda (Merck &#038; Co.) plus Inlyta (Pfizer), and Bavencio (Pfizer \/ Merck KGaA) plus Inlyta, are revolutionizing the treatment of advanced disease. The recent approval and uptake of the Opdivo plus Cabometyx (Exelixis \/ Ipsen) combination will also drive fierce competition in this setting. Multiple immune checkpoint inhibitors are also anticipated to enter the early-stage setting over the forecast period. Additionally, the anticipated entry of other agents such as bempegaldesleukin (Nektar Therapeutics) and belzutifan (Merck &#038; Co.) will further diversify treatment options and create a highly competitive and dynamic market.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What is the size of the advanced or metastatic drug-treatable renal cell carcinoma population, and how will drug-treatment rates change over time?<\/li>\n<li>What is the expected market impact of recent drug approvals and label expansions of novel combinations incorporating Opdivo, Cabometyx, and Keytruda for renal cell carcinoma?<\/li>\n<li>Which are the most promising emerging therapies in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma?<\/li>\n<li>What are the drivers and constraints in the renal cell carcinoma market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast <\/em>provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast <\/em>will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-389928","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-renal-cell-carcinoma","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389928","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389928\/revisions"}],"predecessor-version":[{"id":576313,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389928\/revisions\/576313"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389928"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}